2015 ACR/ARHP Annual Meeting

November 6-11, 2015. San Francisco, CA.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 606

Impaired Kidney Function Improves Treatment Response after 6 Months of Methotrexat Treatment in Rheumatoid Arthritis Patients
Abstract Number: 3214

Impaired Phagocytosis of Apoptotic Cells in Pristane-Induced Lupus Simulates the Clearance Defect in Human SLE
Abstract Number: 838

Impaired Quality of Life in Systemic Sclerosis and Patient Perception of the Disease: A Large International Survey
Abstract Number: 1037

Impaired Regulatory T Cell Survival in the Pathogenesis of Autoreactive Arthritis Mediated By CD11c-Deletion of Flip
Abstract Number: 1492

Implementation in Clinical Practice of a Medication Assessment Tool Specific for Rheumatoid Arthritis, Rhmat
Abstract Number: 125

Implementation of a Bone Health Team Markedly Improves Osteoporosis Screening, Diagnosis and Treatment Initiation Rates Compared to Standard Primary Care Practice
Abstract Number: 2490

Implementation of Disease Activity Measurement for Rheumatoid Arthritis Patients in an Academic Rheumatology Clinic
Abstract Number: 2502

Implementation of New Pneumococcal Vaccination Recommendations in an Academic Rheumatology Clinic
Abstract Number: 2492

Implementation of the Clinical Disease Activity Index to Treat to Target Rheumatoid Arthritis in the Ambulatory Setting: A Plan Do Study Act Quality Analysis
Abstract Number: 1547

Implementing an Electronic Medical Recorded-Based Clinical Decision Support Tool Did Not Improve Cardiovascular Risk Screening in Rheumatoid Arthritis Patients
Abstract Number: 2404

Implications of a Positive Patellar Bulge Sign of Knee Joint Effusion in Patients with Osteoarthritis: Association with MRI Signs of Inflammation and with Increased Rate of 5-Year Total Knee Arthroplasty. Data from the Osteoarthritis Initiative
Abstract Number: 2583

Important Role of CD11c+ Dendritic Cells in Inflammatory Arthritis
Abstract Number: 1036

Important Role of microRNA-146a in Inflammatory Arthritis By Controlling Local Bone Destruction
Abstract Number: 2665

Improved Flare/ Remission Pattern in Rheumatoid Arthritis over the Recent Decades
Abstract Number: 141

Improved Follow-up of Hypertension in Rheumatology Patients: Results of a Pilot

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].